These systemic treatments for melanoma, approved or in experimental phase, include the administration of cytokines and other non-specific immunostimulatory molecules (IL-2, IFN-α2), active immunization (vaccination) with tumor cells, dendritic cells (DCs) or other molecules (recombinant antigens), adoptive transfer of T lymphocytes and monoclonal antibodies against immune checkpoint inhibitors (anti-CTLA-4, anti-PD1, anti-PDL1) (6). Here, IFNA2 is linked to melanoma.